A Phase 2, Double-blind, Randomised, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients with Diabetic Kidney Disease (DKD) who are Receiving Irbesartan
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Propagermanium (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Acronyms ACTION
- Sponsors Dimerix Bioscience
- 13 Sep 2018 Planned End Date changed from 30 Sep 2019 to 27 Dec 2019.
- 13 Sep 2018 Status changed from not yet recruiting to recruiting.
- 15 Jun 2018 New trial record